Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Chlorphenamine + dexamethasone** is a combination drug comprising a first-generation antihistamine (chlorphenamine, also known as chlorpheniramine) and a synthetic glucocorticoid corticosteroid (dexamethasone)[3][8][7]. Chlorphenamine acts as a competitive antagonist at the histamine H1 receptor, thereby reducing allergic symptoms such as itching, sneezing, and rash[3][6]. Dexamethasone binds to the glucocorticoid receptor, inhibiting inflammatory mediators and transcription factors (such as NF-κB and phospholipase A2), and modulating gene expression to produce anti-inflammatory and immunosuppressive effects[1][3][5]. The combination is used for anti-allergic and anti-inflammatory therapy in dermatology and allergy, and in veterinary medicine for symptomatic relief and recovery, particularly in allergy and joint/muscle inflammation[3][8]. The drugs provide synergistic effects, allowing reduced doses of corticosteroids and antihistamines, increasing clinical efficacy and potentially reducing adverse effects[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorphenamine + dexamethasone.